Silver-Russell syndrome (RSS) — sometimes called Russell-Silver syndrome — is a clinically heterogeneous imprinting disorder characterised by severe intrauterine growth restriction (IUGR), poor postnatal growth, relative macrocephaly, a distinctive triangular facial gestalt, and body asymmetry ^[1][2].

Breaking down the name:

• Silver (Henry Silver, 1953) and Russell (Alexander Russell, 1954) independently described children with low birth weight, short stature, and characteristic facial features.
• The eponymous syndrome recognises the overlap between their two cohorts.

Phenotypic expression changes during childhood and adolescence, with the facial features and asymmetry usually becoming more subtle with age ^[2].

• True prevalence is likely underestimated because milder phenotypes go unrecognised, and molecular confirmation is only obtained in ~60% of clinically suspected cases.
• Hong Kong context: RSS is a rare disease but is increasingly recognised with wider availability of methylation-specific testing. The Hospital Authority rare-disease registry and Clinical Genetic Service at QMH/CUHK handle most referrals.

RSS falls under "dysmorphism with a recognizable syndrome" ^[4] and "rare diseases among common diseases" ^[5] in the GC lecture framework.

A systematic approach in paediatrics:

1. Growth assessment: Plot on growth chart — weight, length/height, head circumference. Look for discrepancy between HC (normal) and body size (small) = relative macrocephaly.
2. Dysmorphology examination: Triangular face, clinodactyly, body asymmetry — photograph and document.
3. Feeding and nutritional history: Detailed — caloric intake, GOR symptoms, hypoglycaemia episodes.
4. Developmental assessment: Milestones — motor (often delayed), speech (delayed in matUPD7), cognition (usually normal).
5. Family history: Usually sporadic, but assess for consanguinity and family members with growth issues.
6. Molecular testing: Methylation-specific analysis at 11p15.5 (ICR1) and matUPD7 testing — this will be covered in the Diagnosis section.

Management overview (to be covered in detail in Part 2): GH replacement is the primary growth-promoting treatment ^[1]. Additional management includes nutritional support, hypoglycaemia prevention, orthopaedic follow-up, and monitoring for premature adrenarche.

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 498–500) — Imprinting, UPD, and Russell-Silver syndrome sections ^[2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 855) — Russell-Silver syndrome overview and genetics ^[3] GC lecture slides: CFB (PAE02) Child growth and development.pdf (p. 23) — PICNICS mnemonic, pathological causes of short stature ^[4] GC lecture slides: CFB (PAE02) Child growth and development.pdf (pp. 33–34) — Dysmorphism with a recognizable syndrome, Russell-Silver syndrome ^[5] GC lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 6) — Rare diseases among common diseases, Russell-Silver syndrome listed

Silver-Russell syndrome is not diagnosed by a single lab test or pathognomonic sign. It presents as a constellation of features — IUGR/SGA with failure of catch-up growth, a characteristic facial gestalt, body asymmetry, and feeding difficulty. Each of these features individually overlaps with many other conditions. The clinician's job is to systematically differentiate RSS from other causes of:

1. Intrauterine growth restriction / small-for-gestational-age (SGA) with persistent short stature
2. Dysmorphic syndromes with short stature
3. Body asymmetry (hemihypertrophy/hemihypotrophy)
4. Feeding difficulty with failure to thrive in infancy
5. Relative macrocephaly in a small child

The PICNICS framework from the GC lectures is the backbone for organising the differential of short stature ^[3]:

Pathological causes of short stature — PICNICS: ^[3]

• P — Psychological (deprivation)
• I — Iatrogenic (glucocorticoid usage, spinal radiation)
• C — Chronic illness
• N — Nutritional
• I — IUGR (unknown aetiology or part of a syndrome, e.g., Russell-Silver syndrome)
• C — Chromosomal (Turner syndrome, Noonan syndrome, Down syndrome, Prader-Willi syndrome)
• S — Skeletal dysplasia (achondroplasia, hypochondroplasia)
• + Endocrine — hypothyroidism, growth hormone deficiency, Cushing syndrome ^[3]

RSS is genetically heterogeneous — molecular confirmation is only achievable in ~60% of clinically suspected cases ^[1]. This means a substantial proportion of patients with the clinical phenotype will have negative molecular testing. Therefore, the diagnosis of RSS rests on a clinical scoring system first, with molecular testing used for confirmation and subtype classification rather than as the sole gatekeeper.

Think of it like this: the clinical criteria tell you who to test, and the molecular result tells you the subtype and guides prognosis/genetic counselling.

The Netchine-Harbison Clinical Scoring System (NH-CSS) is the internationally accepted clinical diagnostic framework for RSS, endorsed by the First International Consensus Statement on RSS (2017, Wakeling et al.) and remains current as of 2025 ^[9].

Clinical diagnosis of RSS requires at least 4 out of 6 NH-CSS criteria:

Once clinical criteria are met (≥4/6 NH-CSS), molecular testing is performed in a stepwise fashion:

RSS is genetically heterogeneous, but ~60% are associated with imprinting regions on chromosomes 7 and 11 — e.g., H19 hypomethylation, matUPD7, matdup11p15.5 ^[1]

Understanding why methylation testing is the first-line molecular test:

1. DNA methylation = addition of a methyl group (–CH₃) to cytosine at CpG dinucleotides → methylation makes DNA more tightly bound → ↓ expression ^[1].
2. In RSS, the paternal ICR1 at 11p15.5 should be methylated (allowing IGF-2 expression). When this methylation is lost (hypomethylation/LOM), IGF-2 is silenced → ↓ growth.
3. Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) is the standard method:
   • It simultaneously detects methylation status AND copy number changes at 11p15.5
   • A single test can identify ICR1 LOM, ICR2 abnormalities (important for excluding BWS), and duplications/deletions
4. If MS-MLPA at 11p15.5 is normal → proceed to matUPD7 testing using microsatellite markers or SNP array comparing parental and child DNA

RSS management is fundamentally about optimising the growth and development of a child who is constitutionally small, while preventing and treating complications (hypoglycaemia, feeding failure, premature puberty, orthopaedic problems) and supporting the family. There is no cure — the epigenetic/genetic defect is permanent. Management is therefore:

1. Multidisciplinary — paediatric endocrinology, genetics, dietetics, speech therapy, orthopaedics, developmental paediatrics, orthodontics, psychology
2. Longitudinal — requires follow-up from birth through adolescence (and transition to adult care)
3. Age-dependent — priorities shift as the child grows
4. Family-centred — parents need education, genetic counselling, psychosocial support

RSS is classified as a rare disease ^[1][5] — and like most rare diseases, few specific treatment options exist and management is largely supportive + symptomatic.

Complications in RSS arise from two broad mechanisms:

1. Primary consequences of the underlying epigenetic defect — the imprinting disturbance directly causes growth restriction, metabolic dysregulation, and structural anomalies that in turn lead to complications.
2. Secondary consequences of interventions — GH therapy, although beneficial, can itself produce complications that require monitoring.

Think of it as: the disease causes complications, and the treatment can cause complications. Both need surveillance.

I'll organise complications by system and by age since RSS is a lifelong condition where different complications dominate at different developmental stages.